Clinical trial · Observational
Patterns of ABL Mutation in Asian With Imatinib Resistant Chronic Myeloid Leukemia and Ph Positive Acute Lymphocytc Leuekmia Patients (AMICA)
Patterns of ABL Mutation in Asian With Imatinib Resistant Chronic Myeloid Leukemia and Ph Positive Acute Lymphocytc Leuekmia Patients (AMICA): A Retrospective Feasibility Study
NCT02034656CI-TRIAL-00013420unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purposes of this study are to investigate the patterns of BCR-ABL mutations in CML and Ph positive ALL patients with imatinib resistance during the year of 2001-2009 in Asian institutes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myeloid Leukemia or Ph Positive ALL | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- imatinib resistance
- description
- All mutation data from CML and Ph positive ALL patients who developed imatinib resistance during the year 2001-2009
Primary outcomes (1)
- measure
- Analyzing the patterns and rate of BCR-ABL mutations in Asian CML and Ph positive ALL patients
- timeFrame
- 9 years
- description
- To describe the patterns and rate of BCR-ABL mutations in Asian CML and Ph positive ALL patients. To compare the patterns of BCR-ABL mutations to that of Non-Asian. To describe methods used in mutation analysis
Secondary outcomes (1)
- measure
- Description of the choice of second-line therapy
- timeFrame
- 9 years
- description
- To describe about the choice of second-line therapy To describe outcome after emergence of resistance according to type of mutation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * All mutation data from CML and Ph positive ALL patients who developed imatinib resistance during the year 2001-2009 Exclusion Criteria: * Mutation data from CML and Ph positive ALL patients who, in addition to imatinib, received other therapy. Follow up mutation report after second generation TKI therapy.
References
Publications (0)
Data not yet available
No reference posted for this study.